Suzhou Puhe Pharmaceutical Technology Co., LTD
3 clinical trials · Sponsor
◉ Watch Suzhou Puhe Pharmaceutical Technology Co., LTD
| Record | Firm | Date |
|---|---|---|
| PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT06590194) | Suzhou Puhe Pharmaceutical Technology Co., LTD | 2024-09-10 |
| YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (NCT05767892) | Suzhou Puhe Pharmaceutical Technology Co., LTD | 2023-05-01 |
| Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR (NCT05767866) | Suzhou Puhe Pharmaceutical Technology Co., LTD | 2018-03-30 |
Track Suzhou Puhe Pharmaceutical Technology Co., LTD automatically
Every clearance here is in the API, with alerts when new ones post.